Canal-U

Mon compte

Résultats de recherche

Nombre de programmes trouvés : 2696
Conférences

le (13m7s)

Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 - Workshop 1 : New indications: Is heart failure a viable new potential indication for anti-thrombosis therapy (Efthymios DELIARGYRIS)

... the cellular level, it has been reported that thrombin exerts multiple actions on cardiomyocytes which can favor the genesis of arrhythmias and myocyte injury. Antithrombotic strategies to reduce the risk of death, myocardial infarction (MI), or stroke...
Voir la vidéo
Conférences

le (9m33s)

Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 - Workshop 1 : New indications: Is heart failure a viable new potential indication for anti-thrombosis therapy (Krishna PRASAD)

... the cellular level, it has been reported that thrombin exerts multiple actions on cardiomyocytes which can favor the genesis of arrhythmias and myocyte injury. Antithrombotic strategies to reduce the risk of death, myocardial infarction (MI), or stroke...
Voir la vidéo
Label UNT Conférences

le (17m44s)

Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : Omics research and system biology. Keys for future personalized medicine How future trials may help optimizing benefit-to-risk ratio. The role of specialist scientific organizations.

... systems pharmacology.”Dr Joseph Loscalzo, Lewis A. Conner Lecture, Circulation 2012.- “We need to develop a robust, viable business model through which the pharmaceutical industry can move from drug development strategies that are population-based to...
Voir la vidéo
Label UNT Conférences

le (13m33s)

Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : Omics research and system biology. Keys for future personalized medicine How future trials may help optimizing benefit-to-risk ratio. The role of specialist scientific organizations.

... discipline of systems pharmacology.”Dr Joseph Loscalzo, Lewis A. Conner Lecture, Circulation 2012.- “We need to develop a robust, viable business model through which the pharmaceutical industry can move from drug development strategies that are...
Voir la vidéo
Label UNT Conférences

le (41m46s)

Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : debate Omics research and system biology. Keys for future personalized medicine How future trials may help optimizing benefit-to-risk ratio. The role of specialist scientific organizations.

... from drug development strategies that are population-based to strategies that focus on increasingly individualized therapies. There needs to be an alignment of incentives that move the industry from conventional blockbuster drugs developed in large...
Voir la vidéo

 
FMSH
 
Facebook Twitter
Mon Compte